Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case report: Heparin coagulant super-sensitivity during leech therapy.

Thrombosis journal·2026
Same author

The effect of acetylsalicylic acid on thrombin generation in healthy volunteers.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same author

Biliverdin reductase B as a new target in breast cancer.

Breast cancer research : BCR·2025
Same author

Biliverdin reductase B as a new target in breast cancer.

Research square·2025
Same author

Small molecule BLVRB redox inhibitor promotes megakaryocytopoiesis and stress thrombopoiesis in vivo.

Nature communications·2025
Same author

The Acute Effect of Chamomile Intake on Blood Coagulation Tests in Healthy Volunteers: A Randomized Trial.

The journal of applied laboratory medicine·2024
Same journal

Mitral valve dysplasia associated with left ventricular non-compaction cardiomyopathy and papillary muscle hypertrophy: a case report.

Future cardiology·2026
Same journal

Cardio-oncology awareness: a multidisciplinary survey among trainees and practicing professionals at multidisciplinary settings.

Future cardiology·2026
Same journal

Wearable devices for atrial fibrillation: diagnostic and screening roles of ECG and PPG-A systematic review.

Future cardiology·2026
Same journal

Impact of comorbid mental disorders on in‑hospital mortality and complications after ST‑segment elevation myocardial infarction.

Future cardiology·2026
Same journal

Endovascular revascularisation of lower-extremity peripheral arterial disease: technical and clinical outcomes in a Vietnamese single-center prospective cohort study.

Future cardiology·2026
Same journal

Ultrasound-assisted catheter-directed thrombolysis for pulmonary embolism: current evidence, limitations, and future directions.

Future cardiology·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells
18:30

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells

Published on: February 13, 2013

Platelet transcriptome and cardiovascular disease.

Lisa Senzel1, Dmitri V Gnatenko, Wadie F Bahou

  • 1State University of New York, Department of Pathology, Stony Brook, NY, USA. lsenzel@notes.cc.sunysb.edu

Future Cardiology
|October 7, 2009
PubMed
Summary
This summary is machine-generated.

Platelet hyper-reactivity contributes to cardiovascular disease, but standardized tests are lacking. A novel

More Related Videos

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Related Experiment Videos

Last Updated: Jun 19, 2026

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells
18:30

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells

Published on: February 13, 2013

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Area of Science:

  • Biomedical Engineering
  • Cardiovascular Research
  • Molecular Diagnostics

Background:

  • Platelet hyper-reactivity is implicated in cardiovascular disease pathogenesis.
  • Current diagnostic methods for platelet responsiveness lack standardization.
  • Thrombohemorrhagic disorders require improved characterization tools.

Purpose of the Study:

  • To introduce the development of a 'platelet chip' for high-throughput platelet gene profiling.
  • To assess the potential of the 'platelet chip' in characterizing platelet disorders.
  • To explore future applications in cardiovascular risk stratification and antiplatelet therapy guidance.

Main Methods:

  • Development of a synthetic oligonucleotide microarray representing platelet-specific genes.
  • Utilizing the microarray for high-throughput gene expression analysis in platelets.
  • Characterization of platelet function and genetic profiles.

Main Results:

  • The 'platelet chip' is under development as a tool for comprehensive platelet analysis.
  • This technology enables high-throughput characterization of platelet-based disorders.
  • Potential for detailed analysis of platelet gene expression.

Conclusions:

  • The 'platelet chip' represents a promising advancement in platelet research.
  • Future applications may include improved thrombohemorrhagic risk assessment.
  • Gene profiling could guide personalized antiplatelet therapy for cardiovascular patients.